Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 March 2020 | Story Valentino Ndaba | Photo Sonia Small
Human Rights
Human Rights Month is a time to reflect on the past and celebrate the present.

On 21 March 2020, South Africa will celebrate Human Rights Day. The day has a specific meaning, as it commemorates the Sharpeville massacre which took place on 21 March 1960 in Sharpeville in the Vaal. After the community demonstrated against the pass laws, about 7,000 protesters went to the local police station where the South African Police opened fire on the crowd, killing 69 people and injuring 180.
 
The past, although dark and tragic, holds the power to propel a nation forward. Rector and Vice-Chancellor of the University of the Free State (UFS), Prof Francis Petersen, said: “In remembering this day, we have the opportunity to reflect on progress in the promotion and protection of human rights in South Africa.”
 
Prof Petersen expressed pride in the great strides made at the UFS in this regard and which are cause for celebration. “As a university community, let us join the rest of the country this month and celebrate the rights of all people to be protected from violation, irrespective of gender, race, sexual orientation, religion, etc. Let us observe this day and stand together to promote respect for human rights,” he said.

Policies with a purpose
UFS is guided by principles of non-discrimination and values which seek to uphold the rights of all humans as stipulated in the Constitution of the Republic of South Africa. Staff, students, and the general public enjoy the protection and dignity with policies such as Anti-Discrimination, Promotion of Equality and Social Justice Policy, the Sexual Harassment, Sexual Misconduct and Sexual Violence Policy, the Social Support Policy, as well as the Student Pregnancy Policy.

The objective of the Anti-Discrimination, Promotion of Equality, and Social Justice Policy is to clarify, deepen and promote an understanding of equality, social justice and unfair discrimination among the university community. In addition to other aims, it seeks to identify and promote an understanding of barriers to equality, as well as the various forms and practices of unfair discrimination that may occur. Preventing and eradicating such practices, identifying bullying practices within the various vertical and horizontal relationships at the university, is the policy’s ultimate mandate.

In a country plagued by gender-based violence and related crimes, the Sexual Harassment, Sexual Misconduct and Sexual Violence Policy becomes all the more significant. The policy’s purpose includes establishing a safe and enabling environment, free from sexual harassment, sexual misconduct and sexual violence, for all UFS community members. Support for victims and putting disciplinary procedures for perpetrators in place is a high priority within the policy. 

Human Rights are of utmost importance for a transforming institution such as ours. Hence, the Centre for Universal Access and Disability Support (CUADS) recently released the Social Support Policy Draft for public input. Its overarching goal is to establish an institutional climate and conditions that enable the UFS to retain its students and improve their chances of success by providing appropriate social support. 
 
As far as the Student Pregnancy Policy is concerned, creating conditions that are conducive for academic success and wellbeing during pregnancy is one of the ways in which the university upholds the human rights of mothers-to-be. The policy also ensures that pregnant students are not excluded from academic programmes, residences and other university activities.



News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept